Erika Dyck
Professor and Canada Research Chair in the History of Health & Social Justice at the University of Saskatchewan
Data updated
Research Footprint
Erika Dyck appears in 5 tracked papers (2005–2021), most studied alongside LSD and Mescaline, across Depressive Disorders, Schizophrenia and Alcohol Use Disorder (AUD).
Most-cited paper: ‘Hitting highs at rock bottom’: LSD treatment for alcoholism, 1950-1970 (90 citations).
Frequent co-authors: Milan Scheidegger and Dimitris Repantis.
Background & Research
Erika Dyck is a historian of 20th-century health and medicine in Canada, with research spanning psychedelics, psychiatry, eugenics, population control, and mental health care. She is a professor in the Department of History at the University of Saskatchewan and holds the Canada Research Chair in the History of Health & Social Justice. Her work includes major studies of LSD experimentation and the history of psychedelic therapy in Canada.
Key Impact
She is a leading historian of psychedelic medicine, especially LSD research in Canada, and has helped document the historical links between psychedelics, psychiatry, alcoholism treatment, and end-of-life care.
Collaboration Network
2 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Erika Dyck is associated with.
University of Saskatchewan
The University of Saskatchewan is a public research university located in Saskatoon, Saskatchewan, Canada. Founded in 1907, it is a member of the U15 group of Canadian research universities and offers a wide range of undergraduate and graduate programs.
View stakeholder →McMaster University
A Canadian research university in Hamilton, Ontario, McMaster University houses the Centre for Medicinal Cannabis Research and an expanding psychedelic science program including the McMaster Psychedelic Research Society; the university is sponsoring the PSI_CUD trial—a Phase 2 proof-of-concept study of psilocybin-assisted psychotherapy (two 25mg doses within an 8-week Motivational Enhancement Therapy framework) for cannabis use disorder.
View stakeholder →Chacruna
Non-ProfitChacruna is a nonprofit psychedelic education and advocacy platform based in the United States with global reach through online publishing, courses, conferences, and multilingual programming. Its work centers on psychedelic plant medicines, ethics, cultural justice, reciprocity, and Indigenous knowledge, with content and activities aimed at researchers, clinicians, educators, policy audiences, and the broader public. The organization says it bridges ceremony and science and makes academic knowledge more accessible through public-facing education. Chacruna plays an explicit role in psychedelic justice and policy-adjacent advocacy by foregrounding cultural context, equity, and protection of sacred plants and traditions. Current documented initiatives include the Indigenous Reciprocity Initiative of the Americas, which supports community-led Indigenous projects, the Psychedelic Culture conference, the bilingual Chacruna Latinoamérica platform, and courses on diversity, culture, social justice, ceremony, ethics, and reciprocity. These activities make it a potential partner for researchers, clinicians, funders, and policy groups seeking cultural consultation, educational programming, and community-centered collaboration.
View stakeholder →